Director Renee P. Tannenbaum doubles stake to 20,000 shares in unprofitable CRDF; cluster buy pattern amid +56.2% 30-day rally
Director Renee P. Tannenbaum purchased 10,000 shares at $3.42 on 2024-12-12, doubling her holdings from 10,000 to 20,000 shares. This transaction is part of a cluster buy pattern—2 other insiders also purchased shares within the past 14 days. The purchase occurred after Cardiff Oncology's stock rallied +56.2% over 30 days and +58.7% over 90 days from deeper levels, though the stock remains -31.8% from its 52-week high of $5.91. While the company achieved +26.4% annual revenue growth, it posted a net loss of $-11.9M in its most recent full fiscal year with quarterly revenue of only $165.0K, indicating an early-stage or transitional biotech profile. The convergence of multiple director purchases alongside significant recent price momentum and persistent unprofitability warrants scrutiny of whether this activity reflects fundamentals or opportunistic positioning in a volatile stock.